AbbVie's shareholders can sleep easy.
Zacks Investment Research on MSN
How important are Skyrizi and Rinvoq to AbbVie's Q1 results?
AbbVie’s ABBV immunology franchise remained the company’s biggest growth driver in the first quarter of 2026, which beat expectations for both earnings and sales. The stronger-than-expected sales of ...
Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) and AbbVie (NYSE:ABBV) both posted Q1 2026 results that beat revenue expectations and prompted raised full-year guidance. JNJ leaned on a ...
However, AbbVie's financial results once again highlighted one of the company's strengths that investors should pay attention ...
The season of Skyrizi continues as the treatment for psoriasis, Crohn’s disease and psoriatic arthritis from AbbVie notched the latest quarterly crown for over-the-counter (OTC) pharma and Rx brands.
AbbVie (ABBV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Spot and Tubular data show prescription immunology brands continued to dominate TV, while seasonal OTC brands found scale on ...
UCB’s Bimzelx elicited significantly stronger joint relief at 16 weeks than AbbVie’s Skyrizi in a Phase 3 head-to-head study ...
AbbVie Inc. (NYSE:ABBV) is one of the best low risk stocks to buy in 2026. On May 5, AbbVie presented 18 abstracts at the 2026 Digestive Disease Week Annual Meeting, highlighting new real-world and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results